Our team of medical professionals is evaluating an oral investigational drug called filgotinib to see if it reduces the signs and symptoms of Crohn's disease or UC by lowering the immune response that causes inflammation in the digestive system.
Complete our brief prescreening form to see if you may qualify or learn more below.
The DIVERSITY1 and SELECTION1 studies are evaluating an oral investigational drug called filgotinib for people with moderate to severe Crohn’s disease or ulcerative colitis. Filgotinib is an investigational drug called a “JAK1 inhibitor” that is taken as a pill once a day. JAK1 is a protein inside certain cells, including immune cells, which may stimulate their activity. When these immune cells are overactive, they can cause inflammation and trigger symptoms such as abdominal pain, diarrhea, and bloody stools. These clinical research studies will help determine if filgotinib improves the signs and symptoms of Crohn’s disease and ulcerative colitis.
People who participate in the DIVERSITY1 or SELECTION1 studies may receive filgotinib for approximately one year while continuing to take some of their current drugs. During that time, participants will receive study drug or placebo (an inactive substance that looks like the study drug) and will visit a study doctor 14-21 times at no cost. Participants who respond well and complete one of the studies may have the opportunity to enroll in a long-term extension study in which they will continue taking filgotinib or placebo. Participants who are not responding well after 10 weeks in DIVERSITY1 or SELECTION1 may be eligible to enter the long-term extension study early and receive active filgotinib.
For more study details, visit the page for your condition below, or SEE IF YOU MAY QUALIFY.
For patients with Crohn’s diseaseCLICK TO LEARN MORE
For patients with Ulcerative ColitisCLICK TO LEARN MORE
More information about the studies can also be found at clinicaltrials.gov:
If you meet the criteria based on your responses to our prescreening form, you will be able to provide your contact information to a local doctor conducting the study. Their staff will answer any questions and will further determine if you may qualify. You don’t need health insurance or referrals to participate. However, only study drugs will be provided at no cost, other drugs you are currently taking for your Crohn’s disease or UC, or for other conditions, will not be paid for by the study.
Crohn’s disease is a disorder of the immune system that causes the digestive system to become inflamed. People with Crohn’s disease may experience diarrhea, abdominal pain, or weight loss, among other symptoms. Crohn’s disease is also linked to a higher risk of other intestinal complications.
UC is a disorder of the immune system that causes the colon and rectum to become inflamed. People with UC may experience diarrhea with blood and a constant feeling of needing to use the bathroom. UC is also linked to a higher risk of colorectal cancer.
Doctors use clinical studies to test safety and how well investigational drugs work for specific conditions. In a clinical study, participants may receive investigational drugs that have not yet been approved by Health Canada, the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in Europe. Researchers perform tests and assessments to find out how people respond to the investigational drug.
The DIVERSITY1 study is evaluating a once-daily oral investigational drug called filgotinib to see if it reduces the signs and symptoms of Crohn’s disease. People who participate in the DIVERSITY1 study may have access to study drug and study-related care from a local study doctor. They may also receive reimbursement for study-related travel expenses.
The SELECTION1 study is evaluating a once-daily oral investigational drug called filgotinib to see if it reduces the signs and symptoms of UC. People who participate in the SELECTION1 study may have access to study drug and study-related care from a local study doctor. They may also receive reimbursement for study-related travel expenses.
Clinical research studies are conducted to determine if potential new drugs are safe and if they work. Clinical research studies are performed according to government regulations that help protect the safety and rights of study participants.
A clinical investigator is a medical researcher in charge of conducting a clinical study and ensuring the well-being of study volunteers. The investigators conducting the DIVERSITY and SELECTION clinical studies are all qualified licensed physicians and medical specialists
An investigational drug or research study drug is a drug that has not yet been approved by Health Canada, the Food and Drug Administration (FDA) or European Medicines Agency (EMA) for prescription by doctors. The investigational drug in the DIVERSITY and SELECTION studies is filgotinib.
Yes, participation in any clinical research study is completely voluntary. If you decide to stop participating at any time, your exit will not affect the medical care you would otherwise receive.
Informed consent is the process of learning the key facts and details about a clinical research study. This information will be provided to you before you decide to participate and as new information becomes available during your continued participation throughout the study. Once you have read the informed consent form and understand the details, including the risks and benefits, you can decide whether or not to sign the document. The informed consent process also includes opportunities for you to ask questions about the study. No study-related procedures will take place without a signed informed consent form.
Information about your personal health will be kept private and confidential. With your permission, the information you provide via the prescreening form on this website about your medical history and health condition will be transferred to the study doctor’s office. A representative from the study doctor’s office will contact you to further determine your interest and eligibility. Your personal information will not be disclosed to anyone outside of this clinical research study group without your consent unless disclosure is required by law or regulations of the FDA, EMA, or similar agencies in other countries.
After answering the questions in the prescreening form, you will also have the option to sign up for future updates to be notified about other Crohn's disease and ulcerative colitis clinical studies. Respondents who do not qualify in the online prescreening form, or who are unable to locate a convenient site, will also be able to opt-in for updates which may affect their ability to participate. If you opt to receive these updates, you may receive emails from us in the future but will have the option to decline further communications at any time.
These clinical studies are being conducted to find out whether filgotinib, the investigational drug, is effective in treating the signs and symptoms of Crohn's disease and ulcerative colitis.
Your answers to the questions in the prescreening form will determine if you meet certain key criteria that are required to participate in the DIVERSITY1 or SELECTION1 studies. If you meet these criteria, you can provide your contact information to the participating doctor’s office of your choice via our website. Their staff will then answer any questions you may have and will discuss the next steps to further determine whether you meet all of the criteria for participation. Not all people who complete the prescreening form will be able to participate in one of the studies.
If you meet the criteria in the prescreening form, the staff at the doctor’s office will ask you to review and sign an informed consent form that explains more about the study. Then the staff at the doctor’s office will ask more questions and run some medical tests to see if you meet all eligibility criteria to participate in the clinical research study.
If you qualify for DIVERSITY1 or SELECTION1, you will come to the study doctor’s office for periodic visits for study exams to evaluate your general health and to discuss your Crohn’s disease or ulcerative colitis.
Feel free to discuss your study-related medical care with the study doctor or staff at any time during the course of the research study. It is important to take all study drugs as prescribed. You will answer questions regarding how you feel during your participation and whether the study drugs have been taken at the appropriate times.
The studies each consist of 14-21 visits. The visits are 1-8 weeks apart, over a period of approximately 58 weeks (about one year).
Approximately 1,320 people worldwide will be enrolled in the DIVERSITY1 study, and approximately 1,300 people will be enrolled in SELECTION1 study. These studies are looking for people who have moderate to severe active Crohn's disease or ulcerative colitis.
Reimbursement for study-related travel may be available depending on local practice in your country.
If you participate, study-related doctors’ visits, monitoring of your condition, and the study drug will be provided to you at no cost. You do not need health insurance to participate. Other drugs you may be taking for your Crohn’s disease or ulcerative colitis may not be paid for. The study staff at the participating site will be able to answer any questions you may have.
The choice to participate in this study is entirely yours. Your primary care doctor does not have to give his or her permission or a referral for you to participate in this study. However, you should tell your primary care physician about your participation and keep him or her informed about the study. You should also keep the study doctor informed if your primary care physician changes your Crohn's disease or ulcerative colitis treatment or if there are other changes to your health during the study.
A long-term extension study is a clinical study that allows participants to continue on study drug after they have finished their participation in the original study. After completion of DIVERSITY1 or SELECTION1, participants may have the opportunity to enroll in a long-term extension study of filgotinib in Crohn’s disease or UC.
The study drug, filgotinib, is a JAK1 inhibitor. JAK1 is a protein inside certain cells, including immune cells, which stimulates their activity. When immune cells are overactive, they can cause inflammation and trigger symptoms such as abdominal pain, diarrhea and bloody stools. These clinical research studies will help determine if filgotinib improves the signs and symptoms of Crohn’s disease and ulcerative colitis.
A placebo does not contain any active ingredients and looks the same as the study drug. The use of a placebo is important in clinical research studies because it allows researchers to determine how well the active study drug may be working.
Some people who participate in these studies will receive active investigational drug (filgotinib) and some will receive placebo. Neither you nor the study doctor will be able to choose or know which study group you are in. However, the study doctor can find out if there is an emergency or if it is necessary to know for your health.
You could experience side effects associated with the study drug. The study staff will discuss the known risks in detail with you before you decide to participate.
After a clinical study is complete, all of the information is collected and analyzed to help determine the study drug’s safety and efficacy. Please consult with your study doctor or regular healthcare provider to determine your treatment options after you have completed the study.
The DIVERSITY and SELECTION studies are being conducted by trained, qualified, and licensed medical doctors worldwide.
Gilead Sciences, Inc. and Galapagos NV are developing the investigational study drug and sponsoring these clinical research studies. GILEAD is a trademark of Gilead Sciences, Inc. All other trademarks referenced in this document are the property of their respective owners.